Novartis’ CAR-T cancer therapy Kymriah, which was originally developed at the University of Pennsylvania, can induce long-term remissions in some forms of leukemia and lymphoma, but many patients either relapse or don’t respond at all. Now, Penn researchers are proposing a new method for boosting the response rate to these personalized treatments.

Roivant Sciences has secured $200 million to advance its protein degradation ambitions. Armed with the money, Roivant CEO Vivek Ramaswamy plans to use the VantAI platform to spawn multiple new biotech startups.

Sutro Biopharma’s lead antibody-drug conjugate beat back ovarian cancer in a small phase 1 study, shrinking tumors in 13% of patients who had tried a median of six other treatments.

Everlywell’s sales of at-home diagnostic tests, including one kit for COVID-19, are projected to quadruple this year—and investors have taken notice. The company’s second venture capital round this year has raised $175 million to help accelerate its efforts and expand further into retail stores nationwide.

CAR-T therapies have been a game changer in certain blood cancers, but they aren’t a complete solution. For starters, not all patients can get CAR-T treatment, while others see their cancer worsen despite receiving it.

Many people with Alzheimer’s disease start to suffer a loss of the brain’s white matter—a key regulator of cognition—long before their disease is diagnosed. What if this loss could be detected early and stopped?

4D Molecular Therapeutics raised $75 million in June to get several gene therapy programs into and through the clinic. Now, it’s adding a trio of executives to spearhead its work in heart, eye and lung diseases as it looks to shepherd treatments in those focus areas forward.

After restructuring its heart valve operations and culling one of its programs last year, LivaNova has decided to sell off the flagging business to the Swiss healthcare-focused investment firm Gyrus Capital, for a base purchase price of €60 million, or $73 million U.S.

Janssen has sent off its mutation-specific non-small cell lung cancer drug amivantamab to the FDA.

A Tel Aviv-based venture capital firm focused on digital health has closed a new fund totaling $170 million, and plans to invest in startups across the globe with a new focus on the Asia Pacific region.